Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced results from a systematic ...
The developer of a non-invasive blood-based assay, BCAL hopes to enter the US market by the quicker lab-developed test route.
The group is aiming to raise £900 for charity ...
A new DNA test could help screen whether patients require the treatment or not, according to a new international trial.
Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial ...
A new study linking tattoo ink to cancer risk has sparked concern worldwide. Scientists say the findings are worth watching, ...
In an in-depth interview, Omar Nadeem, MD, explores the promising findings from 20 patients with smoldering myeloma treated with cilta-cel. For decades, patients with smoldering multiple myeloma have ...
FDA approval establishes the first CD123-targeting ADC for BPDCN, with outpatient initiation enabled by an every-3-week IV infusion schedule at 0.045 mg/kg. Frontline CADENZA data showed 69.7% CR/CRc ...
Absolute Investment Advisers receives a Below Average Parent rating. The Parent Pillar assessment is based on a structured evaluation of key factors that influence a firm's ability to support strong ...
With the Xevo TQ Absolute, an instrument that offers absolute performance, users can have complete confidence in reaching lower limits of quantitation for challenging negative ionizing substances. The ...
Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...
mNational Institute for Health Research National Commercial Research Delivery Centre, Bradford, UK nNational Institute for Health Research Manchester Biomedical Research Centre, Manchester University ...